Loading...
Market
What will be the reported effectiveness of the PfSPZ Vaccine in preventing malaria in pregnant women by end of 2025?
2
Resolution / Starting Odds
Less than 50% • 25%
50% to 70% • 25%
71% to 90% • 25%
Above 90% • 25%
Peer-reviewed publications or official announcements from NIAID
Story
Pre-Pregnancy Malaria Vaccine Shows Promise in Mali Trials
Aug 15, 2024, 06:26 AM
Recent findings from a trial conducted in Mali indicate that a pre-pregnancy malaria vaccine, known as the PfSPZ Vaccine, could significantly protect women and their babies from malaria. The research, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), involved two randomized, double-blind, placebo-controlled phase 1 and 2 trials. Scientists have hailed the results as a 'tremendous advance' in preventing the deadly parasitic disease in pregnant women. The trial's success could pave the way for improved malaria prevention strategies for women anticipating pregnancy.
View original story
Similar markets
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
Yes • 50%
No • 50%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Revised guidelines • 25%
Increased studies • 25%
No change • 25%
Other actions • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Highly effective • 25%
Moderately effective • 25%
Slightly effective • 25%
Ineffective • 25%
Successful containment • 25%
Partial containment • 25%
No containment • 25%
Worsening outbreak • 25%
Ivory Coast • 25%
Ghana • 25%
Nigeria • 25%
Other • 25%
